The Holy Grail: highlighting the need for equitable access to dementia treatments and clinical trials
Summary: In the last 5 years significant progress has been made in potential dementia treatments, yet many of these treatments come with significant burdens on the healthcare system that may limit access to treatment and care for patients. Often patients in remote and rural regions and those in low...
Saved in:
Main Authors: | Rebekah M. Ahmed, Olivier Piguet, Catherine J. Mummery, Sharon L. Naismith, Muireann Irish |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-02-01
|
Series: | The Lancet Regional Health. Western Pacific |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S266660652500029X |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tramadol use and incident dementia in older adults with musculoskeletal pain: a population-based retrospective cohort study
by: Si Nae Oh, et al.
Published: (2024-10-01) -
Dementia care recommendations during the COVID-19 pandemic
by: E. Audronytė, et al.
Published: (2020-06-01) -
Coffee and tea consumption and dementia risk: The role of sex and vascular comorbidities
by: Kuan-Chu Hou, et al.
Published: (2025-02-01) -
Frontotemporal dementia: peculiarities of clinical variants
by: B. Klimbytė, et al.
Published: (2021-12-01) -
Reply to “Concerns about methodology and findings in coffee and tea consumption and dementia research”
by: Kuan-Chu Hou, et al.
Published: (2025-02-01)